MedTrace Logo

Action of Amantadine on Post-Stroke Aphasic Patients

NCT00821691 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-04-21

No results posted yet for this study

Summary

The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic patients.

Conditions

  • Cerebral Infarction

Interventions

DRUG

Amantadin

Amantadin caps

DRUG

Placebo

Placebo caps

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Principal Investigators

  • Marcel CHATEL, MDPH · University hospital of Nice

  • Hélène MAHAGNE, PH · University hospital of Nice

  • Sylvain LACHAUD, PH · University hospital of Nice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00821691 on ClinicalTrials.gov